Johnson & Johnson Price to Sales Ratio 2012-2026 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of May 14, 2026 is .
| Johnson & Johnson P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-05-15 | 226.71 | 5.72 | |
| 2026-03-31 | 244.44 | $39.65 | 6.17 |
| 2025-12-31 | 205.86 | $38.84 | 5.30 |
| 2025-09-30 | 183.28 | $38.00 | 4.82 |
| 2025-06-30 | 149.88 | $37.37 | 4.01 |
| 2025-03-31 | 161.35 | $36.83 | 4.38 |
| 2024-12-31 | 139.59 | $36.59 | 3.81 |
| 2024-09-30 | 155.17 | $35.68 | 4.35 |
| 2024-06-30 | 138.89 | $34.80 | 3.99 |
| 2024-03-31 | 149.12 | $33.72 | 4.42 |
| 2023-12-31 | 146.64 | $32.94 | 4.45 |
| 2023-09-30 | 144.56 | $29.30 | 4.93 |
| 2023-06-30 | 152.52 | $28.44 | 5.36 |
| 2023-03-31 | 141.75 | $29.25 | 4.85 |
| 2022-12-31 | 160.40 | $30.01 | 5.34 |
| 2022-09-30 | 147.38 | $28.96 | 5.09 |
| 2022-06-30 | 159.08 | $30.17 | 5.27 |
| 2022-03-31 | 157.81 | $29.89 | 5.28 |
| 2021-12-31 | 151.36 | $29.46 | 5.14 |
| 2021-09-30 | 141.96 | $34.22 | 4.15 |
| 2021-06-30 | 143.95 | $33.39 | 4.31 |
| 2021-03-31 | 142.72 | $31.54 | 4.52 |
| 2020-12-31 | 135.82 | $30.94 | 4.39 |
| 2020-09-30 | 127.60 | $30.25 | 4.22 |
| 2020-06-30 | 119.73 | $30.12 | 3.98 |
| 2020-03-31 | 110.88 | $30.88 | 3.59 |
| 2019-12-31 | 122.56 | $30.55 | 4.01 |
| 2019-09-30 | 107.95 | $30.30 | 3.56 |
| 2019-06-30 | 115.35 | $29.99 | 3.85 |
| 2019-03-31 | 114.99 | $30.01 | 3.83 |
| 2018-12-31 | 105.45 | $29.91 | 3.53 |
| 2018-09-30 | 112.19 | $29.79 | 3.77 |
| 2018-06-30 | 97.87 | $29.51 | 3.32 |
| 2018-03-31 | 102.60 | $28.73 | 3.57 |
| 2017-12-31 | 111.16 | $27.86 | 3.99 |
| 2017-09-30 | 102.80 | $26.99 | 3.81 |
| 2017-06-30 | 103.94 | $26.21 | 3.97 |
| 2017-03-31 | 97.22 | $25.95 | 3.75 |
| 2016-12-31 | 89.34 | $25.74 | 3.47 |
| 2016-09-30 | 90.97 | $25.58 | 3.56 |
| 2016-06-30 | 92.79 | $25.27 | 3.67 |
| 2016-03-31 | 82.19 | $24.98 | 3.29 |
| 2015-12-31 | 77.46 | $24.90 | 3.11 |
| 2015-09-30 | 69.88 | $24.94 | 2.80 |
| 2015-06-30 | 72.40 | $25.29 | 2.86 |
| 2015-03-31 | 74.19 | $25.75 | 2.88 |
| 2014-12-31 | 76.59 | $25.91 | 2.96 |
| 2014-09-30 | 77.56 | $25.91 | 2.99 |
| 2014-06-30 | 75.62 | $25.56 | 2.96 |
| 2014-03-31 | 70.51 | $24.96 | 2.82 |
| 2013-12-31 | 65.27 | $24.78 | 2.63 |
| 2013-09-30 | 61.35 | $24.65 | 2.49 |
| 2013-06-30 | 60.31 | $24.60 | 2.45 |
| 2013-03-31 | 56.84 | $24.30 | 2.34 |
| 2012-12-31 | 48.48 | $24.00 | 2.02 |
| 2012-09-30 | 47.24 | $23.61 | 2.00 |
| 2012-06-30 | 45.90 | $23.32 | 1.97 |
| 2012-03-31 | 44.38 | $23.40 | 1.90 |
| 2011-12-31 | 43.74 | $23.42 | 1.87 |
| 2011-09-30 | 42.09 | $23.17 | 1.82 |
| 2011-06-30 | 43.57 | $22.79 | 1.91 |
| 2011-03-31 | 38.47 | $22.30 | 1.73 |
| 2010-12-31 | 39.80 | $22.06 | 1.80 |
| 2010-09-30 | 39.53 | $22.38 | 1.77 |
| 2010-06-30 | 37.33 | $22.40 | 1.67 |
| 2010-03-31 | 40.84 | $22.40 | 1.82 |
| 2009-12-31 | 40.04 | $22.20 | 1.80 |
| 2009-09-30 | 37.55 | $21.62 | 1.74 |
| 2009-06-30 | 34.75 | $21.84 | 1.59 |
| 2009-03-31 | 31.90 | $22.15 | 1.44 |
| 2008-12-31 | 35.98 | $22.41 | 1.61 |
| 2008-09-30 | 41.32 | $22.54 | 1.83 |
| 2008-06-30 | 38.13 | $22.05 | 1.73 |
| 2008-03-31 | 38.17 | $21.45 | 1.78 |
| 2007-12-31 | 38.99 | $20.94 | 1.86 |
| 2007-09-30 | 38.17 | $20.08 | 1.90 |
| 2007-06-30 | 35.56 | $19.45 | 1.83 |
| 2007-03-31 | 34.55 | $18.76 | 1.84 |
| 2006-12-31 | 37.63 | $17.96 | 2.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |